November 19, 2025 — Leads & Copy —
Neurothera Labs Inc. (TSXV: NTLX), a clinical-stage biotech company and a wholly-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), announced today that Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) has filed an Israeli patent application for an innovative combination therapy addressing depression.
The therapy combines 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines, such as Palmitoylethanolamide (PEA). The patent application is a result of ongoing collaboration between Neurothera and Clearmind Medicine Inc.
The World Health Organization reports that major depressive disorder affects more than 280 million people worldwide and remains a leading cause of disability, with limited innovative treatment options.
The new filing expands the joint intellectual property portfolio developed through the collaboration. To date, 13 patents have been filed under the partnership, focusing on MEAI and N-Acylethanolamines combinations for conditions such as alcohol use disorder, cocaine addiction, obesity and weight loss, and depression. Preclinical data supports MEAI’s efficacy in mitigating addictive behaviors while preserving normal natural reward pathways.
Neurothera Labs Inc. is focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.
Michal Efraty
IR Manager
Neurothera Labs Inc.
Telephone: 972-3-7617108
Email: michal@efraty.com
Source: Neurothera Labs Inc.
